The Centre for Personalized Medicine, Department of Clinical and Experimental Medicine, Division of Pediatrics, Linkoping University, Linkoping, Sweden.
The Centre for Personalized Medicine, Department of Clinical and Experimental Medicine, Division of Pediatrics, Linkoping University, Linkoping, Sweden; Bioinformatics, Department of Physics, Chemistry and Biology, Linkoping University, SE-581 83 Linkoping, Sweden.
J Immunol Res. 2016;2016:5153184. doi: 10.1155/2016/5153184. Epub 2016 Dec 19.
Specific immunotherapy (SIT) reverses the symptoms of seasonal allergic rhinitis (SAR) in most patients. Recent studies report type I interferons shifting the balance between type I T helper cell (Th1) and type II T helper cells (Th2) towards Th2 dominance by inhibiting the differentiation of naive T cells into Th1 cells. As SIT is thought to cause a shift towards Th1 dominance, we hypothesized that SIT would alter interferon type I signaling. To test this, allergen and diluent challenged CD4 T cells from healthy controls and patients from different time points were analyzed. The initial experiments focused on signature genes of the pathway and found complex changes following immunotherapy, which were consistent with our hypothesis. As interferon signaling involves multiple genes, expression profiling studies were performed, showing altered expression of the pathway. These findings require validation in a larger group of patients in further studies.
特异性免疫治疗（SIT）可逆转大多数季节性变应性鼻炎（SAR）患者的症状。最近的研究报告称，I 型干扰素通过抑制初始 T 细胞向 Th1 细胞分化，使 I 型 T 辅助细胞（Th1）和 II 型 T 辅助细胞（Th2）之间的平衡向 Th2 优势转移。由于 SIT 被认为会导致向 Th1 优势的转变，我们假设 SIT 会改变 I 型干扰素信号。为了验证这一点，分析了来自健康对照者和不同时间点的患者的过敏原和稀释剂刺激的 CD4 T 细胞。最初的实验集中在该途径的特征基因上，发现免疫治疗后发生了复杂的变化，这与我们的假设一致。由于干扰素信号涉及多个基因，因此进行了表达谱研究，显示该途径的表达发生了改变。这些发现需要在进一步的研究中在更大的患者群体中进行验证。
